Stanford urine RNA test detects 95 percent of localized bladder cancers and predicts BCG response
A new urine cell-free RNA liquid biopsy called uRARE-seq identified 95 percent of localized bladder cancers in a 683-sample study and predicted which patients would benefit from BCG immunotherapy.